Arlene O. Siefker-Radtke, MD, on Urothelial Bladder Cancer: New Settings for Immune Checkpoint Inhibitors
NCCN 2021 Virtual Annual Conference
Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the changing therapeutic landscape in which atezolizumab, avelumab, and pembrolizumab have either been approved or are under review for treating urothelial bladder cancer in the metastatic, superficial, and adjuvant settings.
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the many considerations when caring for patients with head and neck cancers, such as dental and nutritional issues; side effects from radiation, including necrosis of the bone; oral health; problems with speech; and the concerns of younger patients who may have to cope with the sequelae of treatment such as altered function or disfigurement for years to come.
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses treatment choices for patients with relapsed or refractory CLL/SLL, when to stop therapy due to adverse events, BTK inhibitors and their second-generation counterparts, the need for ways to manage disease progression on novel drugs, and minimal residual disease as a predictor of response.
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss biomarkers for determining treatment; immune checkpoint inhibitors; when to employ such treatments as platinum/fluoropyrimidine and fam-trastuzumab deruxtecan-nxki; and other second- or later-line therapies such as paclitaxel, ramucirumab, irinotecan-based regimens, and trifluridine/tipiracil.
April K. Salama, MD, of Duke Cancer Institute, discusses the shift in recent years, as more effective therapies have become available, toward integrating systemic upfront treatment of patients with brain metastases from cutaneous melanoma; pivotal studies that have provided key data; and the need for a multidisciplinary approach incorporating medical, surgical, and radiation oncology.
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the latest data on treating patients with multiple myeloma, including standard-of-care induction before stem cell transplant; the role of quadruplet induction; long-term results with the combination of daratumumab, lenalidomide, and dexamethasone in those who are ineligible for stem cell transplant; CAR T-cell engagers; and the need for more research on how immunotherapy fits in the sequence of treatments.